Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer

Although platinum-based chemotherapy remains the “standard” in advanced non small-cell lung cancer, not all patients derive clinical benefit from such a treatment. Hence, the development of predictive biomarkers able to identify lung cancer patients who are most likely to benefit from cisplatin-base...

Full description

Bibliographic Details

Published in:	Biomarker Insights
Main Authors:	Christos Papadimitriou, Meletios-Athanasios Dimopoulos, Giannis Mountzios
Format:	Article
Language:	English
Published:	SAGE Publishing 2008-01-01
Subjects:	non small-cell lung cancer ERCC1 predictive biomarkers platinum-based chemotherapy
Online Access:	http://la-press.com/article.php?article_id=712